Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions.

Kopycinski J. et al, (2023), Sci rep, 13

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.

Barnes E. et al, (2023), Nat med, 29, 1760 - 1774

Obesity Differs from Diabetes Mellitus in Antibody and T Cell Responses Post COVID-19 Recovery

Ali M. et al, (2023)

Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses.

Dijokaite-Guraliuc A. et al, (2023), Cell rep, 42

Paediatric HIV slow-progression is associated with early CD8+ T-cell PD-1 expression and a stem-like phenotype.

Adriano Vieira V. et al, (2023), Jci insight

Learning patterns of HIV-1 co-resistance to broadly neutralizing antibodies with reduced subtype bias using multi-task learning

Igiraneza AB. et al, (2023)

The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses.

Murray SM. et al, (2022), Nat rev immunol, 1 - 13

A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117.

Zacharopoulou P. et al, (2022), Curr opin hiv aids, 17, 352 - 358

Booster vaccination against SARS-CoV-2 induces potent immune responses in people with HIV.

Fidler S. et al, (2022), Clin infect dis

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.

Tuekprakhon A. et al, (2022), Cell

An exploration of how broadly neutralizing antibodies might induce HIV remission: the 'vaccinal' effect.

Tipoe T. et al, (2022), Curr opin hiv aids, 17, 162 - 170

BreakAlign: a Perl program to align chimaeric (split) genomic NGS reads and allow visual confirmation of novel retroviral integrations.

Marchi E. et al, (2022), Bmc bioinformatics, 23

The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.

Lee MJ. et al, (2022), Trials, 23

A simple, robust flow cytometry-based whole blood assay for investigating sex differential interferon alpha production by plasmacytoid dendritic cells.

Sampson O. et al, (2022), J immunol methods, 504

Divergent trajectories of antiviral memory after SARS-CoV-2 infection.

Tomic A. et al, (2022), Nat commun, 13

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.

COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk None. and COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium None., (2022), Cell, 185, 916 - 938.e58

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV.

Ogbe A. et al, (2022), Jci insight

Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound.

Zacharopoulou P. et al, (2022), Sci rep, 12

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.

Dejnirattisai W. et al, (2022), Cell

Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruption.

Pace M. et al, (2022), Front immunol, 13

Load More

Include forthcoming?